Spots Global Cancer Trial Database for Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Official Title: A Phase I Dose Escalation Study of Immunotherapy With IMMU-114 in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Study ID: NCT01728207
Interventions
Study Description
Brief Summary: IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Treatment cycles will be repeated until toxicity or worsening of disease.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Helen F Graham Cancer Center, Newark, Delaware, United States
Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, Georgia, United States
Indiana University Health Goshen Hospital, Goshen, Indiana, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Huntsman Cancer Institute, Univ. Utah, Salt Lake City, Utah, United States
Contact Details
Name: William Wegener, MD, PhD
Affiliation: Gilead Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
